(NASDAQ: EQ) Equillium's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.94%.
Equillium's earnings in 2026 is -$22,398,000.On average, 5 Wall Street analysts forecast EQ's earnings for 2026 to be -$18,234,539, with the lowest EQ earnings forecast at -$19,827,848, and the highest EQ earnings forecast at -$15,933,092. On average, 5 Wall Street analysts forecast EQ's earnings for 2027 to be -$18,234,539, with the lowest EQ earnings forecast at -$21,067,088, and the highest EQ earnings forecast at -$14,605,334.
In 2028, EQ is forecast to generate -$28,003,042 in earnings, with the lowest earnings forecast at -$26,643,671 and the highest earnings forecast at -$28,546,790.